Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Orally Available Inhibitors of Factor Xa

18.11.2002


Morphochem AG, a leader in novel chemistries for small molecule drug discovery, has announced that one of its leading programmes, inhibitors of blood coagulation Factor Xa, led to the identification of novel, orally available anti-thrombotics in preclinical studies. Details of these preclinical studies will be presented at a meeting of investment analysts and pharmaceutical executives to be held in Basel on 21st November.
Commenting on the Factor Xa programme, Dr Lutz Weber, CEO of Morphochem said,

"Our strategy is to progress series of compounds into development as we apply the drug discovery engine that we built. The Factor Xa compounds are validating this approach. They have emerged from our protease target platform, are generated by applying our novel MCR chemistries and proprietary MolMind© technologies, and have moved from assay implementation to advanced preclinical compounds in less than three years, a significant achievement."


A novel series of low molecular weight compounds which demonstrate direct inhibition of Factor Xa have been synthesized using Morphochem?s integrated evolutionary chemistry. Data from preclinical studies demonstrate that the lead compounds are highly effective and specific. Good oral availability and reduced side effects were reported. These parameters could lead to significant pharmaco-economic benefits through decreased patient hospitalisation and decreased monitoring of blood coagulation parameters respectively.

Dr Peter Seufer-Wasserthal, Vice President Business Development of Morphochem, commented,

"An orally available inhibitor for Factor Xa is actively sought in the pharmaceutical industry as a cost effective and safe anti-thrombotic. We are now in active discussions with several pharmaceutical companies to explore the optimum strategy for clinical development of our compounds."

The anti-thrombotics market covers a multitude of venous or arterial thrombotic disorders, such as deep vein thrombosis (DVT), unstable angina, myocardial infarction, and stroke. Currently this market is worth over $ 8 billion, with approximately a fifth related to DVT prophylaxis, and therapy in hip and knee surgery. Orally available direct inhibitors of Factor Xa are believed to have a market potential of $ 1 billion in various indication areas.

Charles Consultants | alfa
Further information:
http://www.morphochem.de

More articles from Health and Medicine:

nachricht Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: High-pressure scientists in Bayreuth discover promising material for information technology

Researchers at the University of Bayreuth have discovered an unusual material: When cooled down to two degrees Celsius, its crystal structure and electronic properties change abruptly and significantly. In this new state, the distances between iron atoms can be tailored with the help of light beams. This opens up intriguing possibilities for application in the field of information technology. The scientists have presented their discovery in the journal "Angewandte Chemie - International Edition". The new findings are the result of close cooperation with partnering facilities in Augsburg, Dresden, Hamburg, and Moscow.

The material is an unusual form of iron oxide with the formula Fe₅O₆. The researchers produced it at a pressure of 15 gigapascals in a high-pressure laboratory...

Im Focus: From China to the South Pole: Joining forces to solve the neutrino mass puzzle

Study by Mainz physicists indicates that the next generation of neutrino experiments may well find the answer to one of the most pressing issues in neutrino physics

Among the most exciting challenges in modern physics is the identification of the neutrino mass ordering. Physicists from the Cluster of Excellence PRISMA+ at...

Im Focus: Therapies without drugs

Fraunhofer researchers are investigating the potential of microimplants to stimulate nerve cells and treat chronic conditions like asthma, diabetes, or Parkinson’s disease. Find out what makes this form of treatment so appealing and which challenges the researchers still have to master.

A study by the Robert Koch Institute has found that one in four women will suffer from weak bladders at some point in their lives. Treatments of this condition...

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Physicists from Hannover Predict Novel Light Molecules

26.02.2020 | Physics and Astronomy

Turbomachine expander offers efficient, safe strategy for heating, cooling

25.02.2020 | Power and Electrical Engineering

The seismicity of Mars

25.02.2020 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>